Literature DB >> 15699634

Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min.

Virgil A Marple1, Bernard A Olson, Kumaragovindhan Santhanakrishnan, Daryl L Roberts, Jolyon P Mitchell, Buffy L Hudson-Curtis.   

Abstract

An extension of the archival calibration of the recently developed 30-100-L/min seven-stage impactor, the Next Generation Pharmaceutical Impactor (NGI), has been undertaken at 15 L/min. The NGI stage cut sizes are 0.98-14.1 microm aerodynamic diameter at this flow rate. This 15-L/min calibration was motivated by the desire to sample the entire aerosol produced by a nebulizer when tested in accordance with a new international standard developed by the Comite Européen de Normalisation (CEN), as well as the need to test various types of inhalers at flow rates lower than 30 L/min for pediatric applications. Measurements were undertaken with monodisperse oleic acid droplets in the range of 0.7-22 microm aerodynamic diameter following a procedure established in the original 30-100-L/min calibration study. The NGI was found to be effective for particle size separation at 15 L/min. Users should decide the most applicable configuration that meets their needs, based on the following recommendations: (1) the pre-separator should not normally be used, as its performance is significantly degraded by the influence of gravity, resulting in interference with stage 1; and (2) a filter should be inserted below the micro-orifice collector (MOC), as the size corresponding to 80% collection efficiency of the MOC becomes excessively large with decreasing flow rate, so that this component becomes ineffective as a means of collecting fine particles that penetrate beyond stage 7.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15699634     DOI: 10.1089/jam.2004.17.335

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  12 in total

Review 1.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

Review 2.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

3.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

4.  The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols.

Authors:  D L Roberts; J P Mitchell
Journal:  AAPS PharmSciTech       Date:  2013-03-19       Impact factor: 3.246

5.  Airway deposition of nebulized gene delivery nanocomplexes monitored by radioimaging agents.

Authors:  Maria D I Manunta; Robin J McAnulty; Amy McDowell; Jing Jin; Deborah Ridout; John Fleming; Stephen E Bottoms; Livia Tossici-Bolt; Geoffrey J Laurent; Lorenzo Biassoni; Christopher O'Callaghan; Stephen L Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

6.  Stability and efficacy of synthetic cationic antimicrobial peptides nebulized using high frequency acoustic waves.

Authors:  Ying Wang; Amgad R Rezk; Jasmeet Singh Khara; Leslie Y Yeo; Pui Lai Rachel Ee
Journal:  Biomicrofluidics       Date:  2016-06-07       Impact factor: 2.800

7.  Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform.

Authors:  Christina Cortez-Jugo; Aisha Qi; Anushi Rajapaksa; James R Friend; Leslie Y Yeo
Journal:  Biomicrofluidics       Date:  2015-04-08       Impact factor: 2.800

8.  Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.

Authors:  Maria D I Manunta; Robin J McAnulty; Aristides D Tagalakis; Stephen E Bottoms; Frederick Campbell; Helen C Hailes; Alethea B Tabor; Geoffrey J Laurent; Christopher O'Callaghan; Stephen L Hart
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

9.  Droplet and Aerosol Generation With Mastoidectomy During the COVID-19 Pandemic: Assessment of Baseline Risk and Mitigation Measures With a High-performance Cascade Impactor.

Authors:  Monika E Freiser; Harish Dharmarajan; Devi Sai Sri Kavya Boorgu; Edward S Sim; Timothy E Corcoran; Noel Jabbour; David H Chi
Journal:  Otol Neurotol       Date:  2021-04-01       Impact factor: 2.619

10.  Engineering of Nebulized Metal-Phenolic Capsules for Controlled Pulmonary Deposition.

Authors:  Yi Ju; Christina Cortez-Jugo; Jingqu Chen; Ting-Yi Wang; Andrew J Mitchell; Evelyn Tsantikos; Nadja Bertleff-Zieschang; Yu-Wei Lin; Jiaying Song; Yizhe Cheng; Srinivas Mettu; Md Arifur Rahim; Shuaijun Pan; Gyeongwon Yun; Margaret L Hibbs; Leslie Y Yeo; Christoph E Hagemeyer; Frank Caruso
Journal:  Adv Sci (Weinh)       Date:  2020-01-10       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.